Maida Antigua, M.D.
NPI 1477549061 · Ophthalmology Physician · Hingham, MA
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1477549061
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Female
- Sole proprietor
- Yes
- License
- 40534 (MA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,075 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 320 | $121 |
| Established Patient Problem Focused Exam of Visual System92012 | 303 | $85 |
| Photography of the Retina92250 | 222 | $33 |
| Exam of Visual Field With Extended Testing92083 | 160 | $61 |
| Photography of Content of Eyes92285 | 30 | $22 |
| Removal of Recurring Cataract in Lens Capsule Using a Laser66821 | 20 | $315 |
| Exam of Visual Field With Limited Testing |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 17 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 183 | 55 |
| Timolol Maleate | 83 | 28 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 62 | 22 |
| Cyclosporinebrand: Restasis | 56 | 22 |
| Bimatoprostbrand: Lumigan | 33 | 14 |
| Erythromycin Basebrand: Erythromycin | 30 | 19 |
| Dorzolamide/Timolol/Pfbrand: Dorzolamide-Timolol | 21 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$208 across 6 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-09-20
- Last updated
- 2023-11-13
- Certified
- 2023-11-13
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.